Credit: iStockphoto
BANGKOK: An experimental AIDS vaccine has for the first time cut the risk of infection in humans, but it may still fall short of requirements for an effective preventative.
The vaccine reduces the chance of being infected by a third, researchers said yesterday after a trial of 16,000 volunteers, carried out by the U.S. Army and Thailand's Ministry of Public Health.
The surprising result comes after years of fruitless attempts by the medical world to find a workable HIV vaccine, including one trial jab that apparently increased infection rates.
"Gives us hope"
"It is the first demonstration that a vaccine against HIV can protect against infection," Colonel Jerome Kim of the U.S. military HIV research program told a news conference in Bangkok via videolink.
"This is a very important scientific advance and gives us hope that a globally effective vaccine may be possible in the future," he said.
The vaccine was a combination of two older drugs that had not reduced infection on their own and the researchers said they were now studying why the two apparently worked together.
The study combined the canarypox vaccine ALVAC, manufactured by Sanofi-Aventis of France, and AIDSVAX, originally made by VaxGen Inc and now licensed to the non-profit Global Solutions for Infectious Diseases.
Researchers said the latest vaccine showed a 31.2% efficacy in reducing the risk of HIV infection. "The outcome represents a breakthrough in HIV vaccine development because for the first time ever there is evidence that HIV vaccine has preventative efficacy," the research team said in a statement.
31.2% efficacy
The vaccine was tested on volunteers - all HIV negative men and women aged from 18 to 30 - at average risk of infection in two Thai provinces near Bangkok starting in October 2003. Half received the vaccine and the rest were given a placebo. Out of the placebo recipients 74 of 8,198 became infected compared with 51 of 8,197 who got the vaccine.
The World Health Organisation and the Joint U.N. Program on HIV/AIDS congratulated the researchers for the "encouraging" results. "The study results, representing a significant scientific advance, are the first demonstration that a vaccine can prevent HIV infection in a general adult population and are of great importance," they said in a statement.
The U.N. said it may not be possible to get licensing permission for the drug at the moment based on the results, and that further studies were needed to determine if the vaccine has the same effect in other parts of the world.
AIDS first came to public notice in 1981 and has since killed at least 25 million people worldwide, and 33 million others are living with AIDS or the HIV virus.
Swift progress in identifying the virus that caused AIDS unleashed early optimism that a vaccine would quickly emerge. But out of the 50 candidates that have been evaluated among humans, only two vaccines have made it through all three phases of trials, and both were flops. About 30 vaccines remain in the pipeline.
Scientists were in 2007 forced to abandon two advanced clinical trials of a vaccine by pharmaceutical company Merck after it appeared to actually heighten the risk of AIDS infection.
Heightened risk
The Global HIV Vaccine Enterprise, an alliance of researchers, policymakers, donors and advocates that includes the Bill and Melinda Gates Foundation, said it was an "historic day in the 26-year quest to develop an AIDS vaccine."
The International AIDS Vaccine Initiative (IAVI), an organisation that promotes the search for a vaccine, said the trial results were "very exciting and a significant scientific achievement."
"These new findings represent an important step forward in HIV vaccine research," said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), which provided major funding and logistical support for the study.
Insufficient by a wide margin
Jean-Francois Delfraissy, Director of France's National AIDS Research Agency, also hailed the "good news", but cautioned that the effects remain modest.
However, "we don't yet have a vaccine against HIV," he said. A 31% reduction in the risk of infection "is insufficient by a wide margin. This is not a vaccine tool that can be used by public health services for the population at large."
When deciding whether to license a vaccine, most national health authorities require that a vaccine of any type be at least 70 to 80% effective.
Delfraissy also pointed out that the viral load - the amount of virus in the blood - was the same among those who were infected despite having been vaccinated, as those who were infected in the control group given a placebo.
Follow Cosmos on Twitter! twitter.com/cosmosmagazine
